Drug therapy in Brugada syndrome.
Sudden cardiac death in healthy individuals with structurally normal hearts and a characteristic morphology of the QRS complex resembling a right bundle branch block with elevation of the ST segment in V1 to V3 is known as Brugada syndrome (BrS). Although placement of an implantable cardioverter-defibrillator is considered the only effective therapy for symptomatic patients, some authors have repeatedly reported a beneficial effect of quinidine and isoproterenol in patients with BrS. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their role in the pharmacotherapy of BrS. Other possible agents, mainly I(2) blockers, are also reviewed.
Márquez
Manlio F
MF
Department of Electrocardiology, Instituto Nacional de Cardiología Ignacio Chávez, México. manliomarquez@yahoo.com
Salica
Gabriel
G
Hermosillo
Antonio G
AG
Pastelín
Gustavo
G
Cárdenas
Manuel
M
D002037:Bundle-Branch Block / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000077407:Cilostazol; D004562:Electrocardiography; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D013015:Sotalol / Q000627:therapeutic use; D013577:Syndrome; D013777:Tetrazoles / Q000627:therapeutic use
D013777:Tetrazoles; D008801:Mexiletine; D013015:Sotalol; D007545:Isoproterenol; D000077407:Cilostazol